Literature DB >> 15909927

Examination of antimicrobial activity of selected non-antibiotic drugs.

Hanna Kruszewska1, Tomasz Zareba, Stefan Tyski.   

Abstract

A variety of pharmaceutical preparations, which are applied in the management of non-infectious diseases, have shown in vitro some antimicrobial activity. These drugs are called "non-antibiotics". The aim of this study was to detect and characterize the antimicrobial activity of non-antibiotic drugs, selected from the preparations analysed during state control performed in the National Institute of Public Health in Poland. Over 180 of pharmaceutical preparations were randomly chosen from different groups of drugs. A surveillance study was performed on standard ATCC microbial strains used for drug control: S. aureus, E. coli, P. aeruginosa and C. albicans. It was shown that the drugs listed below inhibited growth of at least one of the examined strains: Actonel 5 mg tabl. (risedronate), Aldan 10 mg tabl. (amlodipine), Aleras 10 mg tabl. (cetirisine), Aspicam 15 mg tabl. (meloxicam), Baikadent 6 mg/g gel (flavons of Scutellariae), Debretin 100 mg tabl. (trimebutine), Ferro-Duo 100 mg tabl. (ferrum), Gastrovent 145 mg caps. (bismuth citrate), Ibum 200 mg caps., Upfen 200 mg tabl. (ibuprofen), Lastet 100 mg caps. (etoposide), Legalon 70 mg tabl. (sylimarin), Madopar 125 tabl. (benserazide, levodopa), Moxenil 100 mg tabl. (nimesulide), Neurotin 800 mg tabl. (gabapentin), Propranolol 40 mg tabl. (propranolol), Rexetin 20 mg tabl. (paroxetine), Salipax 20 mg caps. (fluoxetine), Selofen 10 mg caps. (zaleplon) Stenorol 0.6% powder (halofuginone), Stimuloton 50 mg tabl. (sertraline), Superoptim 0.3 mg tabl. (hipericine), Uversan 50 mg tabl. (arbutine from Arctostaphylos uva ursi). S. aureus strain was susceptible to the most of the drugs listed above. The lowest inhibitory concentration was found for sertraline and hipericine (0.16 and 0.075 mg/mL, respectively).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15909927

Source DB:  PubMed          Journal:  Acta Pol Pharm        ISSN: 0001-6837            Impact factor:   0.330


  13 in total

1.  Cell Wall-active Bacteriocins and Their Applications Beyond Antibiotic Activity.

Authors:  Clara Roces; Ana Rodríguez; Beatriz Martínez
Journal:  Probiotics Antimicrob Proteins       Date:  2012-12       Impact factor: 4.609

2.  Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy.

Authors:  Linda Ejim; Maya A Farha; Shannon B Falconer; Jan Wildenhain; Brian K Coombes; Mike Tyers; Eric D Brown; Gerard D Wright
Journal:  Nat Chem Biol       Date:  2011-04-24       Impact factor: 15.040

3.  In vitro antibacterial effects of statins against bacterial pathogens causing skin infections.

Authors:  Humphrey H T Ko; Ricky R Lareu; Brett R Dix; Jeffery D Hughes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-22       Impact factor: 3.267

4.  The promising anti-virulence activity of candesartan, domperidone, and miconazole on Staphylococcus aureus.

Authors:  Amira M El-Ganiny; Amany I Gad; Mona A El-Sayed; Moataz A Shaldam; Hisham A Abbas
Journal:  Braz J Microbiol       Date:  2021-11-13       Impact factor: 2.476

5.  Antifungal Effects and Potential Mechanisms of Benserazide Hydrochloride Alone and in Combination with Fluconazole Against Candida albicans.

Authors:  Xueqi Chen; Jiyong Wu; Lei Sun; Jing Nie; Shan Su; Shujuan Sun
Journal:  Drug Des Devel Ther       Date:  2021-11-16       Impact factor: 4.162

6.  Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis.

Authors:  Hao-Chieh Chiu; Jian Yang; Shilpa Soni; Samuel K Kulp; John S Gunn; Larry S Schlesinger; Ching-Shih Chen
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

7.  Trimebutine as a potential antimicrobial agent: a preliminary in vitro approach.

Authors:  J Kountouras; D Sofianou; E Gavalas; E Sianou; C Zavos; G Meletis; E Tsiaousi
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

8.  Gut microbes in neurocognitive and mental health disorders.

Authors:  Tyler Halverson; Kannayiram Alagiakrishnan
Journal:  Ann Med       Date:  2020-08-31       Impact factor: 4.709

9.  Statins: antimicrobial resistance breakers or makers?

Authors:  Humphrey H T Ko; Ricky R Lareu; Brett R Dix; Jeffery D Hughes
Journal:  PeerJ       Date:  2017-10-24       Impact factor: 2.984

10.  The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders.

Authors:  Jannis Kountouras; Emmanouel Gavalas; Michael Doulberis; Stergios A Polyzos; Apostolis Papaefthymiou; Maria Touloumtzi; Elisabeth Vardaka; Konstantinos Kountouras; Katerina Papanikolopoulou; Panagiotis Katsinelos
Journal:  J Neurogastroenterol Motil       Date:  2019-07-01       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.